
Artemis Structural Intelligence is developing a platform that gives owners, operators and engineers ongoing visibility into the condition of high-value structures — replacing single-point-in-time inspections with a continuous signal of structural change. The platform combines permanently installed sensing, structural baselining, impedance interrogation, cloud analytics and artificial intelligence to convert physical structures into sources of actionable information.
Most structures share a common limitation: they give little indication of their own condition between scheduled inspections. Owners, operators and engineers are often left making decisions on incomplete information — maintenance schedules and inspection intervals help, but they can't show how a structure is changing in the gaps between them.
Real-world validation through deployment in the Heysen Tunnel, South Australia, testing performance under harsh operating conditions.
Ongoing technical work with the University of Adelaide supporting fracture mechanics and impedance-based assessment.
Direct engineering engagement with United Airlines has helped shape the aviation commercial pathway around real operational needs.
Engagement with Boeing has added insight into structural health monitoring, certification logic and the route to aviation adoption.
A manufacturing partnership with Baylin/Galtronics gives Artemis scalable production without building infrastructure from scratch.
The platform builds on more than 15 years of engineering, marine construction and infrastructure project experience.
Artemis' flagship commercial platform and largest long-term opportunity, addressing the growing burden of structural inspections across ageing commercial aircraft fleets.
Expected to provide the earliest path to commercial revenue, applying the same architecture to tunnels, bridges, transport and energy infrastructure.
Strategic expansion potential across vehicle fleets, defence readiness and autonomous systems — viewed as future upside rather than the near-term focus.
Artemis is not seeking to replace inspections, non-destructive testing or engineering judgement. Traditional inspection methods remain mature, trusted and necessary — but they are episodic. Artemis aims to provide an additional, continuous layer of structural intelligence in the gaps between inspection events.
Commercial aviation is one of the largest recurring structural asset management markets in the world, with tens of thousands of commercial aircraft in service and ageing fleets driving more frequent, complex inspection requirements. Beyond aviation, infrastructure operators manage trillions of dollars in long-lived assets where better structural visibility can support life extension, maintenance optimisation and capital planning — the opportunity RELIABLE is built to address.
Management views commercial aviation as Artemis' largest strategic opportunity, given the scale of ageing fleets, rising maintenance costs and growing adoption of condition-informed maintenance. The commercial strategy centres on a focused entry point — the Boeing 737NG chem-mill inspection programme — chosen for its large fleet size, fatigue-sensitive structures and measurable operational burden, with additional aircraft programmes identified for future expansion.

Founder & Chief Executive Officer
Darren brings extensive practical experience across marine construction, industrial operations, infrastructure projects, commercial diving, environmental compliance, government engagement and university-linked technical programmes.
To learn more about Implicit Bioscience and their recent updates, visit their website below.
This document serves as the primary information memorandum for Implicit Bioscience, providing key details about the company's business model, operations, investment structure, and associated risks. It outlines the terms of the investment opportunity and is intended to support informed decision-making by prospective investors.
This form lets you apply to invest in the fund — covering your details, investment amount, banking info, and compliance declarations. Read it with the Information Memorandum first; submitting it means you accept the fund's terms.
Connecting institutional, accredited, and high-net-worth investors with carefully vetted opportunities across pharma and agribiotech.
© 2026 Opportunity-Plus Investment Fund (OPIF). All rights reserved.